

CITATION REPORT

List of articles citing

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

DOI: 10.1038/s41586-020-2381-y
Nature, 2020, 584, 120-124.

Source: <https://exaly.com/paper-pdf/75892567/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1099	High Potency of a Bivalent Human V Domain in SARS-CoV-2 Animal Models. 2020 , 183, 429-441.e16		67
1098	Multisystem Inflammatory Syndrome in Children and SARS-CoV-2 Serology. 2020 , 146,		7
1097	Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. 2020 , 370,		289
1096	Toward Understanding Molecular Bases for Biological Diversification of Human Coronaviruses: Present Status and Future Perspectives. 2020 , 11, 2016		10
1095	Viruses That Can and Cannot Coexist With Humans and the Future of SARS-CoV-2. 2020 , 11, 583252		8
1094	Early predictors for mechanical ventilation in COVID-19 patients. 2020 , 14, 1753466620963017		6
1093	Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. 2020 , 1, 100126		134
1092	2020 update on human coronaviruses: One health, one world. 2020 , 8, 100043		12
1091	Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2. 2020 , 10, 17806		27
1090	Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. 2020 , 117, 28046-28055		110
1089	An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain. 2020 , 33, 108274		107
1088	REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. 2020 , 370, 1110-1115		330
1087	Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions. 2020 , 41, 1006-1022		46
1086	A systematic review of SARS-CoV-2 vaccine candidates. 2020 , 5, 237		257
1085	A materials-science perspective on tackling COVID-19. 2020 , 1-14		123
1084	A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2. 2020 , 5, 218		18
1083	Broad host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2. 2020 , 6, 68		69

1082	Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. 2020 , 117, 25254-25262	116
1081	Structural basis of a shared antibody response to SARS-CoV-2. 2020 , 369, 1119-1123	338
1080	Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. 2020 , 182, 843-854.e12	185
1079	The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. 2020 , 182, 1284-1294.e9	899
1078	Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction. 2021 , 12, 586-591	8
1077	Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys. 2020 , 11, 5752	40
1076	Global SNP analysis of 11,183 SARS-CoV-2 strains reveals high genetic diversity. 2021 , 68, 3288-3304	29
1075	Immunopathology, host-virus genome interactions, and effective vaccine development in SARS-CoV-2. 2020 , 18, 3774-3787	11
1074	SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. 2020 , 10, 587269	199
1073	Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. 2020 , 53, 1272-1280.e5	112
1072	Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be. 2020 , 7, 605236	60
1071	SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. <i>Nature</i> , 2020 , 588, 682-687	50.4 651
1070	A Hydrophobic-Interaction-Based Mechanism Triggers Docking between the SARS-CoV-2 Spike and Angiotensin-Converting Enzyme 2. 2020 , 4, 2000067	9
1069	Dissecting the Drug Development Strategies Against SARS-CoV-2 Through Diverse Computational Modeling Techniques. 2020 , 329	4
1068	Approaches and Challenges in SARS-CoV-2 Vaccine Development. 2020 , 28, 364-370	64
1067	Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges. 2020 , 13, 957-975	5
1066	Striking Similarities between CDRs in Some mAbs That Neutralize COVID-19. 2020 , 11, 1663-1666	2
1065	Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications. 2020 , 13,	47

1064	COVID-19: Mechanisms of Vaccination and Immunity. 2020 , 8,	43
1063	Need for Speed: From Human SARS-CoV-2 Samples to Protective and Efficacious Antibodies in Weeks. 2020 , 182, 7-9	
1062	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. 2020 , 383, 1544-1555	612
1061	Identification of an anti-SARS-CoV-2 receptor-binding domain-directed human monoclonal antibody from a naïve semisynthetic library. 2020 , 295, 12814-12821	32
1060	Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2. 2020 , 41, 815-829	66
1059	A thermostable, closed SARS-CoV-2 spike protein trimer. 2020 , 27, 934-941	128
1058	Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. 2021 , 73, e531-e539	125
1057	Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. 2020 , 182, 1295-1310.e20	935
1056	Potently neutralizing and protective human antibodies against SARS-CoV-2. <i>Nature</i> , 2020 , 584, 443-449	50.4 609
1055	Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. 2020 , 117, 29832-29838	57
1054	Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines. 2020 , 11, 579250	50
1053	Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. 2020 , 5, 1598-1607	667
1052	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. 2020 , 217,	289
1051	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. 2020 , 88, 106980	20
1050	Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. 2020 , 370, 1227-1230	680
1049	The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies. 2020 , 9,	29
1048	Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. 2020 , 11, 5413	105
1047	Neurological injuries in COVID-19 patients: direct viral invasion or a bystander injury after infection of epithelial/endothelial cells. 2020 , 26, 631-641	18

1046	Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. 2020 , 5, 180	151
1045	A mouse model for SARS-CoV-2 infection by exogenous delivery of hACE2 using alphavirus replicon particles. 2020 , 30, 1046-1048	14
1044	An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. 2020 , 11, 4420	151
1043	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. 2020 , 370, 950-957	314
1042	A Perspective on Application of Carbon Quantum Dots in Luminescence Immunoassays. 2020 , 8, 580033	4
1041	Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. 2020 , 5, 212	59
1040	Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. 2020 , 183, 1013-1023.e13	145
1039	Human B Cell Clonal Expansion and Convergent Antibody Responses to SARS-CoV-2. 2020 , 28, 516-525.e5	121
1038	Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. <i>Nature</i> , 2020 , 585, 584-587.4	198
1037	Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2. 2021 , 25, 415-421	19
1036	Antibody-like proteins that capture and neutralize SARS-CoV-2. 2020 , 6,	12
1035	Targeting multiple epitopes on the spike protein: a new hope for COVID-19 antibody therapy. 2020 , 5, 208	2
1034	Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds. 2020 , 12,	32
1033	Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective. 2020 , 11, 570018	23
1032	De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. 2020 , 370, 426-431	219
1031	Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice. 2020 , 12,	9
1030	Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. 2020 , 5, 1185-1191	329
1029	Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma. 2020 , 15, e0238089	41

1028	An IgA mimicry of IgG that binds Polymeric Immunoglobulin Receptor for mucosa transcytosis. 2020 , 3, 157-162	1
1027	COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19. 2020 , 3, 205-212	58
1026	A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction. 2020 , 11, 4198	69
1025	Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic. 2020 , 3, 246-256	14
1024	SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. 2020 , 11, 569760	12
1023	A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters. 2020 , 11, 614256	25
1022	May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)?. 2020 , 18, 489	4
1021	Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies. 2020 , 131, e116	57
1020	Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. 2020 , 12, 1854149	79
1019	Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2. 2020 , 9,	11
1018	Host metabolism dysregulation and cell tropism identification in human airway and alveolar organoids upon SARS-CoV-2 infection. 2021 , 12, 717-733	33
1017	Man-Specific, GalNAc/T/Tn-Specific and Neu5Ac-Specific Seaweed Lectins as Glycan Probes for the SARS-CoV-2 (COVID-19) Coronavirus. 2020 , 18,	10
1016	Antibody Mutagenesis for Optimizing Its Binding to Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2. 2020 , 11, 9781-9787	13
1015	Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2. 2020 , 11, 5588	73
1014	Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping. 2020 , 2020, 9465398	18
1013	A compendium answering 150 questions on COVID-19 and SARS-CoV-2. 2020 , 75, 2503-2541	58
1012	A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. 2020 , 182, 722-733.e11	227
1011	COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds. 2020 , 94,	63

1010	Adaptive immunity to SARS-CoV-2. 2020 , 1, iqaa003	5
1009	A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. 2020 , 205, 915-922	126
1008	Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. 2020 , 26, 1422-1427	283
1007	COVID-19: Progress in diagnostics, therapy and vaccination. 2020 , 10, 7821-7835	77
1006	Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. 2020 , 257, 118056	89
1005	Recent insights for the emerging COVID-19: Drug discovery, therapeutic options and vaccine development. 2021 , 16, 4-23	30
1004	Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment. 2021 , 296, 100025	24
1003	Characteristics of SARS-CoV-2 and COVID-19. 2021 , 19, 141-154	1287
1002	Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. 2021 , 538, 192-203	93
1001	Review of COVID-19 Antibody Therapies. 2021 , 50, 1-30	15
1000	Antibodies at work in the time of severe acute respiratory syndrome coronavirus 2. 2021 , 23, 101-110	11
999	Generation of a cost-effective cell line for support of high-throughput isolation of primary human B cells and monoclonal neutralizing antibodies. 2021 , 488, 112901	4
998	Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. 2021 , 184, 169-183.e17	327
997	Neutralizing monoclonal antibodies for COVID-19 treatment and prevention. 2021 , 44, 7-17	20
996	D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. 2021 , 29, 23-31.e4	198
995	Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection. 2021 , 31, 25-36	53
994	Structure-based development of human antibody cocktails against SARS-CoV-2. 2021 , 31, 101-103	45
993	Letter to the editor: Neutralizing antibodies for the treatment of COVID-19. 2021 , 11, 304-307	9

992	Rapid generation of ACE2 humanized inbred mouse model for COVID-19 with tetraploid complementation. 2021 , 8, nwaa285	8
991	Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. 2021 , 538, 187-191	39
990	Nanozyme chemiluminescence paper test for rapid and sensitive detection of SARS-CoV-2 antigen. 2020 , 173, 112817	88
989	Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. 2021 , 169, 100-117	25
988	The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition. 2021 , 433, 166748	5
987	Protoporphyrin IX and verteporfin potentially inhibit SARS-CoV-2 infection and in a mouse model expressing human ACE2. 2021 , 66, 925-936	11
986	Recent Insights into Emerging Coronavirus: SARS-CoV-2. 2021 , 7, 1369-1388	13
985	COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research. 2021 , 16, 25-35	4
984	IgA dominates the early neutralizing antibody response to SARS-CoV-2. 2021 , 13,	405
983	Enhanced SARS-CoV-2 neutralization by dimeric IgA. 2021 , 13,	178
982	Recent advances in immunotherapies against infectious diseases. 2021 , 1,	9
981	Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak. 2021 , 26, 311-329	0
980	Viral targets for vaccines against COVID-19. 2021 , 21, 73-82	402
979	Neutralizing antibodies targeting SARS-CoV-2 spike protein. 2020 , 50, 102125	35
978	The scientific and ethical feasibility of immunity passports. 2021 , 21, e58-e63	49
977	Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2. 2021 , 17, 113-121	42
976	COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays. 2021 , 41, 5-28	43
975	ACE2 Can Act as the Secondary Receptor in the FcR-Dependent ADE of SARS-CoV-2.	

974	Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses. 2021 , 1322, 219-260	1
973	Lysine β -Hydroxybutyrylation Improves Stability of COVID-19 Antibody.	
972	Impact of South African 501.V2 Variant on SARS-CoV-2 Spike Infectivity and Neutralization: A Structure-based Computational Assessment.	35
971	The role and uses of antibodies in COVID-19 infections: a living review. 2021 , 2, iqab003	5
970	Standardization of ELISA protocols for serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood sampling. 2021 , 12, 113	54
969	Impact of New Variants on SAR-CoV-2 Infectivity and Neutralization: A Molecular Assessment of the Alterations in the Spike-Host Protein Interactions.	1
968	A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351. 2021 , 13, 1930636	7
967	The scientific research progress of novel coronavirus SARS-COV-2. 2021 , 245, 03052	
966	Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. 2021 , 12, 469	74
965	Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies. 2021 , 12, 6929-6948	37
964	COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. 2021 , 40, 905-919	109
963	Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals. 2020 , 11, 618685	29
962	Binding affinity and mechanisms of SARS-CoV-2 variants. 2021 , 19, 4184-4191	5
961	Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. 2021 ,	154
960	A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice. 2021 , 7, 183-199	60
959	Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. 2021 ,	28
958	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. 2021 , 28, 9	52
957	The evolutionary making of SARS-CoV-2.	

956	Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial. 2021 , 11, e297	32
955	The cellular immune response to COVID-19 deciphered by single cell multi-omics across three UK centres.	7
954	The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates. 2021 ,	27
953	Targeting protein-protein interaction interfaces in COVID-19 drug discovery. 2021 , 19, 2246-2255	8
952	A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge. 2021 , 10, 1555-1573	2
951	Effect of SARS-CoV-2 spike mutations on animal ACE2 usage and in vitro neutralization sensitivity.	15
950	Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. 2021 , 12, 264	41
949	Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV. 2021 , 13, 1953683	8
948	Overview of Nonhuman Primate Models of SARS-CoV-2 Infection. 2021 , 71, 411-432	1
947	Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein. 2021 , 19, 33	27
946	50 Years of structural immunology. 2021 , 296, 100745	3
945	Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. 2021 , 13,	30
944	Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates. 2021 , 15, 2738-2752	57
943	Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses. 2021 ,	14
942	SARS-CoV-2 structural features may explain limited neutralizing-antibody responses. 2021 , 6, 2	23
941	Interaction of serum proteins with SARS-CoV-2 RBD. 2021 , 13, 12865-12873	1
940	ACE2 Can Act as the Secondary Receptor in the FcR-Dependent ADE of SARS-CoV-2.	
939	Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2. 2021 , 13, 1893426	7

938	Accurate Evaluation on the Interactions of SARS-CoV-2 with Its Receptor ACE2 and Antibodies CR3022/CB6*. 2021 , 38, 018701	13
937	SARS-CoV-2 infection and disease outcomes in non-human primate models: advances and implications. 2021 , 10, 1881-1889	1
936	A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent. 2021 , 28, 202-209	46
935	Cryo-EM Structures of the N501Y SARS-CoV-2 Spike Protein in Complex with ACE2 and Two Potent Neutralizing Antibodies.	5
934	Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients. 2021 , 10, 1097-1111	6
933	Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies.	97
932	Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy. 2021 , 18, 660-674	5
931	Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. 2021 ,	32
930	A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. 2021 , 12, 288	108
929	Stereotypic neutralizing V antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals. 2021 , 13,	36
928	Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library.	1
927	Molecular Mechanism of the N501Y Mutation for Enhanced Binding between SARS-CoV-2 Spike Protein and Human ACE2 Receptor.	20
926	SARS-CoV-2 spike protein N501Y mutation causes differential species transmissibility and antibody sensitivity: a molecular dynamics and alchemical free energy study.	4
925	SARS-CoV-2 receptor binding mutations and antibody mediated immunity.	3
924	Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat RBD of SARS-CoV-2 spike protein protects mice against COVID-19.	
923	Homologous and heterologous serological response to the N-terminal domain of SARS-CoV-2.	
922	High-Throughput, Single-Copy Sequencing Reveals SARS-CoV-2 Spike Variants Coincident with Mounting Humoral Immunity during Acute COVID-19. 2021 ,	2
921	A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.	3

920	A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. 2021 , 12, 776	26
919	Digestive system involvement of infections with SARS-CoV-2 and other coronaviruses: Clinical manifestations and potential mechanisms. 2021 , 27, 561-575	1
918	Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library. 2021 , 30, 716-727	8
917	Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin-Kallikrein System in Severe COVID-19. 2021 , 13,	11
916	In search for the SARS-CoV-2 protection correlate: A head-to-head comparison of two quantitative S1 assays in a group of pre-characterized oligo-/asymptomatic patients.	5
915	Long-term sero-positivity for IgG, sequelae of respiratory symptoms, and abundance of malformed sperms in a patient recovered from severe COVID-19. 2021 , 40, 1559-1567	4
914	A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus macaques.	1
913	Potent in vitro Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain.	2
912	Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir. 2021 , 2, 100080	20
911	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. 2021 ,	26
910	Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. 2021 , 371, 850-854	395
909	Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies. 2021 ,	37
908	Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. 2021 , 325, 632-644	443
907	COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. 2021 ,	10
906	SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys. 2021 ,	4
905	Insights on SARS-CoV-2 Mutations for Evading Human Antibodies: Sacrifice and Survival.	6
904	An Optimized High-Throughput Immuno-Plaque Assay for SARS-CoV-2. 2021 , 12, 625136	14
903	Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. 2021 , 371, 735-741	130

902	Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses. 2021,	5
901	In silico analysis suggests less effective MHC-II presentation of SARS-CoV-2 RBM peptides: Implication for neutralizing antibody responses. 2021, 16, e0246731	3
900	COVID-19 mRNA vaccines. 2021, 48, 107-114	24
899	SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. 2021, 9,	62
898	Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. 2021, 371, 823-829	157
897	Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. 2021,	28
896	Multispecific DARPIn \square therapeutics demonstrate very high potency against SARS-CoV-2 variants in vitro.	4
895	Nanotraps for the containment and clearance of SARS-CoV-2.	1
894	Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants. 2021,	13
893	A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. 2021,	47
892	Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19. 2021, 12, 574425	13
891	Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies : Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations.	1
890	SARS-CoV-2 virus: Vaccines in development. 2021, 1, 131-138	6
889	Effects of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike on its Binding Affinity to ACE2 and Neutralizing Antibodies Revealed by Computational Analysis.	2
888	Insights into biological therapeutic strategies for COVID-19. 2021, 1, 166-178	2
887	Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain. 2021,	19
886	Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects. 2021,	4
885	Modelling the population-level protection conferred by COVID-19 vaccination.	2

884	A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes. 2021 ,	26
883	A recombinant receptor-binding domain in trimeric form generates completely protective immunity against SARS-CoV-2 infection in nonhuman primates.	1
882	All-Atom Simulations and Free-Energy Calculations of Antibodies Bound to the Spike Protein of SARS-CoV-2: The Binding Strength and Multivalent Hydrogen-Bond Interactions. 2021 , 4, 2100012	1
881	Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants. 2021 ,	3
880	SARS-CoV-2 seroassay optimization and performance in a population with high background reactivity in Mali. 2021 ,	3
879	Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates. 2021 , 7,	32
878	Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection. 2021 , 60, 10266-10272	44
877	Nicotinic cholinergic system and COVID-19: In silico identification of interactions between α 7 nicotinic acetylcholine receptor and the cryptic epitopes of SARS-CoV and SARS-CoV-2 Spike glycoproteins. 2021 , 149, 112009	19
876	Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients. 2021 , 34, 108915	56
875	Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. 2021 , 29, 463-476.e6	569
874	A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2. 2021 , 17, e1009328	17
873	A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2. 2021 , 12, 653189	11
872	SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usage.	8
871	Approaching the Interpretation of Discordances in SARS-CoV-2 Testing. 2021 , 8, ofab144	1
870	A SARS-CoV-2 Spike Binding DNA Aptamer that Inhibits Pseudovirus Infection by an RBD-Independent Mechanism. 2021 , 133, 10367-10373	7
869	Performance Characteristics of the Vidas SARS-CoV-2 IgM and IgG Serological Assays. 2021 , 59,	8
868	Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection. 2021 , 133, 10354-10360	10
867	Live Imaging of SARS-CoV-2 Infection in Mice Reveals Neutralizing Antibodies Require Fc Function for Optimal Efficacy. 2021 ,	10

866	Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein. 2021 , 7, e06564	13
865	Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. 2021 , 184, 1201-1213.e14	110
864	mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. 2021 , 372,	217
863	Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope. 2021 , 13,	11
862	A SARS-CoV-2 Spike Binding DNA Aptamer that Inhibits Pseudovirus Infection by an RBD-Independent Mechanism*. 2021 , 60, 10279-10285	43
861	Drug development of an affinity enhanced, broadly neutralizing heavy chain-only antibody that restricts SARS-CoV-2 in rodents.	4
860	SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. 2021 , 12, 1577	28
859	Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies. 2021 ,	24
858	A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2. 2021 , 8, nwab053	13
857	Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks. 2021 , 16, 398-411	9
856	REGEN-COV protects against viral escape in preclinical and human studies.	8
855	Drug discovery and development targeting the life cycle of SARS-CoV-2. 2021 , 1, 151-165	3
854	Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies. 2021 , 31, 517-525	20
853	Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters. 2021 , 2, 100218	20
852	Structure, Dynamics, Receptor Binding, and Antibody Binding of the Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein in a Viral Membrane. 2021 , 17, 2479-2487	26
851	Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies. 2021 ,	27
850	Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization. 2021 ,	79
849	Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. <i>Nature</i> , 2021 , 593, 130-135	50.4 997

848	Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues. 2021 , 372, 738-741	22
847	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. 2021 ,	2
846	Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants.	1
845	Polymersomes decorated with SARS-CoV-2 spike protein receptor binding domain elicit robust humoral and cellular immunity. 2021 ,	1
844	Recent advances in nanomaterials based biosensors for point of care (PoC) diagnosis of Covid-19 - A minireview. 2021 , 137, 116205	32
843	Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class. 2021 , 35, 108950	38
842	Coronavirus disease 2019 and the revival of passive immunization: Antibody therapy for inhibiting severe acute respiratory syndrome coronavirus 2 and preventing host cell infection: IUPHAR review: 31. 2021 , 178, 3359-3372	8
841	Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. 2021 , 29, 551-563.e5	42
840	Neutralizing monoclonal antibodies for treatment of COVID-19. 2021 , 21, 382-393	227
839	NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodies. 2021 , 22, e52325	12
838	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. 2021 , 13,	169
837	Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. 2021 , 184, 1821-1835.e16	16
836	SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. 2021 , 184, 2362-2371.e9	197
835	Dynamic Profiling of Binding and Allosteric Propensities of the SARS-CoV-2 Spike Protein with Different Classes of Antibodies: Mutational and Perturbation-Based Scanning Reveal Allosteric Duality of Functionally Adaptable Hotspots.	
834	Inactivating SARS-CoV-2 by electrochemical oxidation. 2021 , 66, 720-726	6
833	Smarter cures to combat COVID-19 and future pathogens: a review. 2021 , 19, 1-13	12
832	Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19. 2021 , 2, 100253	18
831	Integrated Biophysical Modeling of the SARS-CoV-2 Spike Protein Binding and Allosteric Interactions with Antibodies. 2021 , 125, 4596-4619	16

830	Neutralizing Antibody Therapeutics for COVID-19. 2021 , 13,	44
829	Synthetic Homogeneous Glycoforms of the SARS-CoV-2 Spike Receptor-Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies. 2021 , 133, 13014-13020	1
828	Epitope profiling of coronavirus-binding antibodies using computational structural modelling.	5
827	Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes. 2021 , 18, 87	15
826	Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles. 2021 , 9,	10
825	A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope. 2021 ,	6
824	Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge. 2021 , 66, 103291	9
823	Enhanced binding of the N501Y-mutated SARS-CoV-2 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations. 2021 , 595, 1454-1461	80
822	Single-Cell RNA Sequencing Analysis of the Immunometabolic Rewiring and Immunopathogenesis of Coronavirus Disease 2019. 2021 , 12, 651656	7
821	Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies. 2021 , 19, e3001237	92
820	The antigenic anatomy of SARS-CoV-2 receptor binding domain. 2021 , 184, 2183-2200.e22	145
819	Structural insights into SARS-CoV-2 infection and therapeutics development. 2021 , 52, 102219	3
818	Potent germline-like monoclonal antibodies: rapid identification of promising candidates for antibody-based antiviral therapy. 2021 , 4, 89-98	
817	Epitope classification and RBD binding properties of neutralizing antibodies against SARS-CoV-2 variants of concern.	1
816	Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond. 2021 , 40, 36-49	4
815	Antibody Cocktail Exhibits Broad Neutralization against SARS-CoV-2 and SARS-CoV-2 variants.	1
814	Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drive rapid and potent immunogenicity capable of single-dose protection.	2
813	SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses. 2021 , 2, 100252	17

812	Antibodies and Vaccines Target RBD of SARS-CoV-2. 2021 , 8, 671633	32
811	Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. 2021 , 184, 1804-1820.e16	149
810	Revealing the threat of emerging SARS-CoV-2 mutations to antibody therapies. 2021 ,	8
809	Co-infection of H9N2 Influenza A Virus and in a BALB/c Mouse Model Aggravates Lung Injury by Synergistic Effects. 2021 , 12, 670688	5
808	A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain. 2021 , 12, 647934	18
807	High-throughput, single-copy sequencing reveals SARS-CoV-2 spike variants coincident with mounting humoral immunity during acute COVID-19. 2021 , 17, e1009431	18
806	Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma. 2021 , 12,	24
805	Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. 2021 , 20, 88	12
804	Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants. 2021 , 290, 114084	1
803	Insights into SARS-CoV-2's Mutations for Evading Human Antibodies: Sacrifice and Survival. 2021 ,	26
802	Computational epitope map of SARS-CoV-2 spike protein. 2021 , 17, e1008790	36
801	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. 2021 , 184, 2348-2361.e6	549
800	Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. 2021 , 2, 100255	205
799	CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity.	
798	One dose of COVID-19 nanoparticle vaccine REVC-128 provides protection against SARS-CoV-2 challenge at two weeks post immunization.	4
797	Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodies.	18
796	Synthetic repertoires derived from convalescent COVID-19 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modality. 2021 ,	4
795	The Mechanisms and Animal Models of SARS-CoV-2 Infection. 2021 , 9, 578825	13

794	Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies: Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations. 2021 , 60, 1459-1484	17
793	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. 2021 ,	13
792	Intermolecular Interaction Analyses on SARS-CoV-2 Spike Protein Receptor Binding Domain and Human Angiotensin-Converting Enzyme 2 Receptor-Blocking Antibody/Peptide Using Fragment Molecular Orbital Calculation. 2021 , 12, 4059-4066	10
791	Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape. 2021 ,	12
790	Synthetic Homogeneous Glycoforms of the SARS-CoV-2 Spike Receptor-Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies. 2021 , 60, 12904-12910	14
789	Scrutinizing Coronaviruses Using Publicly Available Bioinformatic Tools: The Viral Structural Proteins as a Case Study. 2021 , 8, 671923	
788	Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B.	2
787	Identification and characterization of a monoclonal antibody blocking the SARS-CoV-2 spike protein-ACE2 interaction. 2021 , 18, 1562-1564	4
786	SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms. 2021 , 184, 2605-2617.e18	74
785	Dynamics of B cell repertoires and emergence of cross-reactive responses in patients with different severities of COVID-19. 2021 , 35, 109173	14
784	SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. <i>Nature</i> , 2021 , 595, 421-425.0.4	197
783	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. <i>Nature</i> , 2021 , 594, 553-559.0.4	85
782	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. 2021 , 373, 818-823	148
781	Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. 2021 , 29, 747-751.e4	277
780	SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination.	48
779	Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections. 2021 , 13,	4
778	Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection. 2021 , 8, 670815	5
777	New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection. 2021 , 14,	3

776	A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes. 2021 , 12, 2623	25
775	Problems associated with antiviral drugs and vaccines development for COVID-19: approach to intervention using expression vectors via GPI anchor. 2021 , 40, 665-706	5
774	Fc-independent neutralization of SARS-CoV-2 by recombinant human monoclonal antibodies.	2
773	Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses. 2021 , 12, 662909	
772	Rapid isolation and immune profiling of SARS-CoV-2 specific memory B cell in convalescent COVID-19 patients via LIBRA-seq. 2021 , 6, 195	10
771	Tapping the immunological imprints to design chimeric SARS-CoV-2 vaccine for elderly population. 2021 , 1-16	1
770	Potent and Persistent Antibody Response in COVID-19 Recovered Patients. 2021 , 12, 659041	2
769	Current Strategies of Antiviral Drug Discovery for COVID-19. 2021 , 8, 671263	24
768	Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic.. 2021 , 1, 100027	4
767	Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins. 2021 , 11, 10475	2
766	In Silico Molecular-Based Rationale for SARS-CoV-2 Spike Circulating Mutations Able to Escape Bamlanivimab and Etesevimab Monoclonal Antibodies.	2
765	Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2. 2021 , 35, 109109	7
764	On the road to ending the COVID-19 pandemic: Are we there yet?. 2021 , 557, 70-85	18
763	Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11. 2021 , 7,	19
762	Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization. 2021 , 4, 597	13
761	COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy. 2021 , 15, 27	23
760	SARS -CoV-2 T-cell immunity to variants of concern following vaccination. 2021 ,	16
759	Mapping Potential Antigenic Drift Sites (PADS) on SARS-CoV-2 Spike in Continuous Epitope-Paratope Space. 2021 ,	


758	Rapid and reliable hybridoma screening method that is suitable for production of functional structure-recognizing monoclonal antibody. 2021 , 131, 696-702	1
757	Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis. 2021 , 44, 392-400	5
756	Identification of Cross-Reactive CD8 T Cell Receptors with High Functional Avidity to a SARS-CoV-2 Immunodominant Epitope and Its Natural Mutant Variants. 2021 ,	8
755	SARS-CoV-2 and Plasma Hypercoagulability. 2021 , 1-10	6
754	Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain. 2021 , 12, 3815	15
753	Immunological imprinting of the antibody response in COVID-19 patients. 2021 , 12, 3781	51
752	Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers. 2021 , 12, 3661	14
751	Undiagnosed SARS-CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States. 2021 , 13,	34
750	Perspectives on passive antibody therapy and peptide-based vaccines against emerging pathogens like SARS-CoV-2. 2021 , 11, 287-305	1
749	Probing Affinity, Avidity, Anti-Cooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses.	1
748	SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model. 2021 , 223, 2020-2028	16
747	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.	37
746	A Cross-Sectional Study of SARS-CoV-2 Seroprevalence between Fall 2020 and February 2021 in Allegheny County, Western Pennsylvania, USA. 2021 , 10,	4
745	Structure-based Design of a Specific, Homogeneous Luminescence Enzyme Reporter Assay for SARS-CoV-2. 2021 , 433, 166983	0
744	FXa cleaves the SARS-CoV-2 spike protein and blocks cell entry to protect against infection with inferior effects in B.1.1.7 variant. 2021 ,	2
743	The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. 2021 , 16, e0253487	31
742	In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic Patients. 2021 , 10, 1505-1518	23
741	Potent neutralizing RBD-specific antibody cocktail against SARS-CoV-2 and its mutant. 2021 , 2, 442	3

740	Advances in Neutralization Assays for SARS-CoV-2. 2021 , 94, e13088	10
739	Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection. 2021 , 12, 697074	5
738	A bifluorescent-based assay for the identification of neutralizing antibodies against SARS-CoV-2 variants of concern in vitro and in vivo.	1
737	The first Chinese national standards for SARS-CoV-2 neutralizing antibody. 2021 , 39, 3724-3730	3
736	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. <i>Nature</i> , 2021 , 596, 103-108	50.4 91
735	Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. 2021 , 6, 233	60
734	Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes. 2021 , 12, e0069621	37
733	Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2. 2021 , 12, 3802	28
732	SARS-CoV-2: Origin, Evolution, and Targeting Inhibition. 2021 , 11, 676451	6
731	Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern. 2021 , 12, 691715	17
730	Animal models for SARS-CoV-2. 2021 , 48, 73-81	24
729	Nanotraps for the containment and clearance of SARS-CoV-2. 2021 , 4, 2059-2082	14
728	Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia. 2021 , 184, 3192-3204.e16	16
727	The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. 2021 , 12, 687869	9
726	Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species. 2021 , 184, 3438-3451.e10	30
725	Dynamic Profiling of Binding and Allosteric Propensities of the SARS-CoV-2 Spike Protein with Different Classes of Antibodies: Mutational and Perturbation-Based Scanning Reveals the Allosteric Duality of Functionally Adaptable Hotspots. 2021 , 17, 4578-4598	7
724	Tackling COVID-19 with neutralizing monoclonal antibodies. 2021 , 184, 3086-3108	108
723	Improving the safety and security of fruits and vegetables during COVID-19 pandemic with postharvest handling. 2021 , 1-11	2

722	Increased lung cell entry of B.1.617.2 and evasion of antibodies induced by infection and BNT162b2 vaccination.	7
721	The serological diversity of serum IgG/IgA/IgM against the SARS-CoV-2 nucleoprotein, spike, and receptor-binding domain and neutralizing antibodies in patients with COVID-19 in Japan.	2
720	SARS-CoV-2 Antiviral Therapy. 2021 , e0010921	12
719	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. 2021 , 373,	80
718	Production of scFv, Fab, and IgG of CR3022 Antibodies Against SARS-CoV-2 Using Silkworm-Baculovirus Expression System. 2021 , 63, 1223-1234	2
717	Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects Macaques from infection.	
716	SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain. 2021 , 207, 878-887	8
715	Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries. 2021 , 7, 57	10
714	Molecular characterization of interactions between the D614G variant of SARS-CoV-2 S-protein and neutralizing antibodies: A computational approach. 2021 , 91, 104815	5
713	SARS-CoV-2 receptor-binding mutations and antibody contact sites. 2021 , 4, 149-158	5
712	Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. 2021 , 385, 1382-1392	196
711	Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing. 2021 , 6, 13	1
710	Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. 2021 , 17, e1009688	7
709	Therapeutic antibodies under development for SARS-CoV-2. 2021 , 20200178	2
708	Dimeric IgA is a specific biomarker of recent SARS-CoV-2 infection. 2021 ,	4
707	Key substitutions in the spike protein of SARS-CoV-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effects.	5
706	New Impedimetric Sandwich Immunosensor for Ultrasensitive and Highly Specific Detection of Spike Receptor Binding Domain Protein of SARS-CoV-2. 2021 , 7, 3874-3885	8
705	Reshaping cell line development and CMC strategy for fast responses to pandemic outbreak. 2021 , 37, e3186	4

704	Comparison of infected and vaccinated transplant recipients highlights the role of Tfh and neutralizing IgG in COVID-19 protection.	3
703	Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies. 2021 , 29, 655-663.e4	36
702	Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy. 2021 , 11, 697876	8
701	Discovery of nanobodies against SARS-CoV-2 and an uncommon neutralizing mechanism.	
700	Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection. 2021 ,	1
699	Atomistic Simulations and Deep Mutational Scanning of Protein Stability and Binding Interactions in the SARS-CoV-2 Spike Protein Complexes with Nanobodies: Molecular Determinants of Mutational Escape Mechanisms.	
698	SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. 2021 , 36, 109415	131
697	Antibody and B cell responses to SARS-CoV-2 infection and vaccination. 2021 , 29, 1063-1075	30
696	Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular Immunity. 2021 , 7, 1368-1380	5
695	A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. 2021 , 13,	21
694	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. 2021 , 12, 4196	106
693	The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes.	3
692	Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein. 2021 , 4, 1349-1361	0
691	Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. 2021 , 36, 109353	41
690	Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants. 2021 , 36, 934-947	3
689	Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative. 2021 , 7, 2546-2564	8
688	Recent progress of surface plasmon resonance in the development of coronavirus disease-2019 drug candidates. 2021 , 1, 100003	3
687	Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates. 2021 ,	7

686	Molecular Insights into COVID-19 Pathophysiology, Immune Pathogenesis, Detection, and Treatment. 2021 , 40, 858-868	
685	Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques.	4
684	The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. 2021 , 184, 3949-3961.e11	78
683	Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study. 2021 , 65, e0035021	7
682	A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. 2021 , 36, 109433	25
681	A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection. 2021 , 12, 4635	15
680	Cornering an Ever-Evolving Coronavirus: TATX-03, a fully human synergistic multi-antibody cocktail targeting the SARS-CoV-2 Spike Protein with in vivo efficacy.	1
679	Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. 2021 , 21, 475-484	143
678	Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. 2021 , 54, 1611-1621.e5	85
677	SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. <i>Nature</i> , 2021 , 597, 97-102 50.4	118
676	SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies May Ameliorate COVID-19 Complications in APECED Patients. 2021 , 12, 720205	6
675	Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2. 2021 , 12, 715464	4
674	A recombinant receptor-binding domain in trimeric form generates protective immunity against SARS-CoV-2 infection in nonhuman primates. 2021 , 2, 100140	3
673	A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants. 2021 , 12, 5000	7
672	Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients. 2021 , 12, 723585	3
671	In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. 2021 , 184, 4203-4219.e32	89
670	SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment. 2021 ,	25
669	Cross-neutralization of RBD mutant strains of SARS-CoV-2 by convalescent patient derived antibodies. 2021 , 16, e2100207	4

668	Potential for Developing Plant-Derived Candidate Vaccines and Biologics against Emerging Coronavirus Infections. 2021 , 10,	4
667	Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics. 2021 , 12, 4887	8
666	Immunity against seasonal human coronavirus OC43 mitigates fatal deterioration of COVID-19. 2021 , 109, 261-268	5
665	Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review. 2021 , 9,	6
664	Computational insights into binding mechanism of drugs as potential inhibitors against SARS-CoV-2 targets. 2021 , 1-11	0
663	Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS-CoV-2 Variants. 2021 , 4, 2100099	6
662	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. 2021 , 54, 1853-1868.e7	83
661	N439K Variant in Spike Protein Alter the Infection Efficiency and Antigenicity of SARS-CoV-2 Based on Molecular Dynamics Simulation. 2021 , 9, 697035	11
660	Development of test kit for detection of specific IgM to SARS-CoV-2 by immune blotting in the  format. 2021 , 66, 472-479	
659	Analysis of the molecular mechanism of SARS-CoV-2 antibodies. 2021 , 566, 45-52	1
658	Reduced serum neutralization capacity against SARS-CoV-2 variants in a multiplex ACE2 RBD competition assay.	4
657	A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site. 2021 , 54, 2385-2398.e10	14
656	Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. <i>Nature</i> , 2021 , 598, 342-347 ^{50.4}	63
655	Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection. 2021 , 7, 71	7
654	Computational design of SARS-CoV-2 peptide binders with better predicted binding affinities than human ACE2 receptor. 2021 , 11, 15650	5
653	Integrated single-cell analysis revealed immune dynamics during Ad5-nCoV immunization. 2021 , 7, 64	3
652	Mutations of SARS-CoV-2 RBD May Alter Its Molecular Structure to Improve Its Infection Efficiency. 2021 , 11,	7
651	An Adverse Outcomes Approach to Study the Effects of SARS-CoV-2 in 3D Organoid Models. 2021 , 434, 167213	0

650	Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection. 2021 , 43, 1706-1727	15
649	COVID-19 Research: Lessons from Non-Human Primate Models. 2021 , 9,	4
648	Comparison of Wild Type DNA Sequence of Spike Protein from SARS-CoV-2 with Optimized Sequence on The Induction of Protective Responses Against SARS-Cov-2 Challenge in Mouse Model.	
647	Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect in a Mouse Model in a Neutralization-Dependent Manner. 2021 , 12, e0100221	2
646	Two-dimensional multiplexed assay for rapid and deep SARS-CoV-2 serology profiling and for machine learning prediction of neutralization capacity. 2021 ,	
645	Refining the N-Termini of the SARS-CoV-2 Spike Protein and Its Discrete Receptor-Binding Domain. 2021 , 20, 4427-4434	1
644	A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. 2021 , 54, 2399-2416.e6	30
643	A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro. 2021 , 29, 951-962.e3	13
642	Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen. 2021 , 12, 707977	6
641	No substantial pre-existing B cell immunity against SARS-CoV-2 in healthy adults.	
640	A highly potent antibody effective against SARS-CoV-2 variants of concern. 2021 , 37, 109814	9
639	B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination. 2021 , 37, 109825	31
638	Similar antibody responses against SARS-CoV-2 in HIV uninfected and infected individuals on antiretroviral therapy during the first South African infection wave. 2021 ,	6
637	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. 2021 , 36, 109760	29
636	An ultrapotent pan-Ecoronavirus lineage B (ECoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. 2021 , 1	2
635	A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques.	
634	Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. 2021 , 54, 2143-2158.e15	37
633	Pathomechanisms, therapeutic targets and potent inhibitors of some beta-coronaviruses from bench-to-bedside. 2021 , 93, 104944	3

632	Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2. 2021 , 186, 490-500	11
631	Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. 2021 , 6, 1233-1244	72
630	Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters. 2021 , 12, e0239521	5
629	Atomistic Simulations and In Silico Mutational Profiling of Protein Stability and Binding in the SARS-CoV-2 Spike Protein Complexes with Nanobodies: Molecular Determinants of Mutational Escape Mechanisms. 2021 , 6, 26354-26371	2
628	Neutralizing antibodies for the prevention and treatment of COVID-19. 2021 , 18, 2293-2306	21
627	Advancements in detection of SARS-CoV-2 infection for confronting COVID-19 pandemics. 2021 ,	4
626	A non-RBM targeted RBD specific antibody neutralizes SARS-CoV-2 inducing S1 shedding. 2021 , 571, 152-158	3
625	Neutralizing antibody responses following natural SARS-CoV-2 infection: Dynamics and correlation with commercial serologic tests. 2021 , 144, 104988	7
624	A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2.	19
623	Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity. 2021 ,	8
622	Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving TNF- α inhibitors.	1
621	A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern and. 2021 , 95, e0112621	2
620	Application of Human Induced Pluripotent Stem Cell-Derived Cellular and Organoid Models for COVID-19 Research. 2021 , 9, 720099	1
619	Structural biology of SARS-CoV-2 and implications for therapeutic development. 2021 , 19, 685-700	38
618	Tetavalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations. 2021 , 433, 167177	10
617	Activation Pathways and Free Energy Landscapes of the SARS-CoV-2 Spike Protein. 2021 , 6, 23432-23441	2
616	Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. 2021 , 33, 529-540	5
615	Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants. 2021 , 12, 5652	11

614	Do we need bamlanivimab? Is etesevimab a key to treating Covid-19?. 2021 , 21, 1359-1362	2
613	Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis. 2021 , 28, 1379-1388.e7	14
612	Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses. 2021 , 37, 109771	20
611	Antibody Response against SARS-CoV-2 Infection: Implications for Diagnosis, Treatment and Vaccine Development. 2021 , 1-21	0
610	Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity reduces lung inflammation. 2021 ,	3
609	Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody. 2021 , 12, 751584	5
608	Development of a novel label-free all-fiber optofluidic biosensor based on Fresnel reflection and its applications. 2021 , 1181, 338910	1
607	Cell entry by SARS-CoV-2. 2021 , 46, 848-860	34
606	Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2). 2021 , 192, 114724	2
605	Oligonucleotide aptamers: Recent advances in their screening, molecular conformation and therapeutic applications. 2021 , 143, 112232	6
604	Track-etched membrane microplate and smartphone immunosensing for SARS-CoV-2 neutralizing antibody. 2021 , 192, 113550	1
603	Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain. 2021 ,	0
602	Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19. 2021 , 10, 1574-1588	3
601	Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice. 2021 , 63, 103197	11
600	VarEPS: an evaluation and prewarning system of known and virtual variations of SARS-CoV-2 genomes. 2021 ,	2
599	Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate. 2021 , 9,	12
598	Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages. 2021 , 21, e4	16
597	Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody. 2021 , 10, 1638-1648	6

596	Immunogenicity and protective efficacy of a highly thermotolerant, trimeric SARS-CoV-2 receptor binding domain derivative.	
595	Mutations in spike protein and allele variations in ACE2 impact targeted therapy strategies against SARS-CoV-2. 2021 , 42, 170-181	0
594	Mapping a Pandemic: SARS-CoV-2 Seropositivity in the United States. 2021 ,	11
593	SARS-CoV-2 Seroassay Optimization and Performance in a Population with High Background Reactivity in Mali.	0
592	Development and application of therapeutic antibodies against COVID-19. 2021 , 17, 1486-1496	16
591	Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. 2021 , 2, 1	6
590	Potent mouse monoclonal antibodies that block SARS-CoV-2 infection. 2021 , 296, 100346	9
589	Development and Characterization of a Quantitative ELISA to Detect Anti-SARS-CoV-2 Spike Antibodies.	
588	Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination. 2021 , 10, 1390-1403	8
587	An overview of methods for the structural and functional mapping of epitopes recognized by anti-SARS-CoV-2 antibodies.. 2021 , 2, 1580-1589	0
586	Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry. 2021 , 12, 250	45
585	Complexities of the COVID-19 vaccine and multisystem inflammatory syndrome in children. 2020 , 4, 299-300	7
584	An Overview of the Crystallized Structures of the SARS-CoV-2. 2020 , 39, 600-618	17
583	Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?. 2020 , 63, 1833-1849	13
582	COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine. 2020 , 35, 685-698	6
581	COVID-19 in clinical practice: A narrative synthesis. 2020 , 50, 639-647	1
580	Correlates of protection against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2021 , 590, 630-634	50.4 498
579	Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide. 2020 , 40,	17

578	Cross-species recognition of SARS-CoV-2 to bat ACE2. 2021 , 118,	32
577	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. 2021 , 218,	171
576	Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective. 2020 , 3, 285-299	16
575	The development of neutralizing antibodies against SARS-CoV-2 and their common features. 2020 , 12, 980-986	5
574	Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2. 2021 , 8, nwa297	14
573	Protoporphyrin IX and verteporfin prevent SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2.	4
572	Development of a vaccine against the newly emerging COVID-19 virus based on the receptor binding domain displayed on virus-like particles.	12
571	An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.	19
570	Ultra-sensitive nanozyme-based chemiluminescence paper test for rapid diagnosis of SARS-CoV-2 infection.	4
569	SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.	8
568	Synthetic antibodies neutralize SARS-CoV-2 infection of mammalian cells.	8
567	Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike. 2020 ,	9
566	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. 2020 ,	35
565	Structural basis of a public antibody response to SARS-CoV-2. 2020 ,	14
564	A potent synthetic nanobody targets RBD and protects mice from SARS-CoV-2 infection.	16
563	IgA dominates the early neutralizing antibody response to SARS-CoV-2.	54
562	Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. 2020 ,	15
561	A thermostable, closed, SARS-CoV-2 spike protein trimer.	6

560	Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma.	5
559	Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. 2020,	33
558	Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2.	11
557	Map of SARS-CoV-2 spike epitopes not shielded by glycans.	11
556	Cryo-EM Structures Delineate a pH-Dependent Switch that Mediates Endosomal Positioning of SARS-CoV-2 Spike Receptor-Binding Domains. 2020,	28
555	Human B cell clonal expansion and convergent antibody responses to SARS-CoV-2. 2020,	4
554	Structures of potent and convergent neutralizing antibodies bound to the SARS-CoV-2 spike unveil a unique epitope responsible for exceptional potency.	6
553	Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection.	146
552	Linear epitope landscape of SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients.	7
551	Dynamics of B-cell repertoires and emergence of cross-reactive responses in COVID-19 patients with different disease severity. 2021,	2
550	SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months.	82
549	Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralization. 2020,	15
548	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. 2020,	32
547	D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization.	21
546	An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain. 2020,	8
545	An antibody-dependent enhancement (ADE) activity eliminated neutralizing antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys.	5
544	Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19.	1
543	SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses.	11

542	Engineered ACE2 receptor traps potentially neutralize SARS-CoV-2. 2020,	9
541	Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay. 2020,	8
540	REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters.	15
539	Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity. 2020,	13
538	De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. 2020,	9
537	Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals. 2020,	6
536	Pharmacological inhibition of the kinin-kallikrein system in severe COVID-19 [A proof-of-concept study.	2
535	Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. 2020,	38
534	Attenuated influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in mice. 2020,	2
533	Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment immunogen.	1
532	A rapid and efficient screening system for neutralizing antibodies and its application for the discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD.	8
531	SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model.	16
530	Highly potent anti-SARS-CoV-2 multivalent DARPin therapeutic candidates.	9
529	A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice. 2020,	14
528	Structural classification of neutralizing antibodies against the SARS-CoV-2 spike receptor-binding domain suggests vaccine and therapeutic strategies. 2020,	18
527	Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro. 2020,	15
526	A key linear epitope for a potent neutralizing antibody to SARS-CoV-2 S-RBD.	3
525	Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates. 2021,	8

524	Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection. 2020,	21
523	SARS-CoV-2 antibody signatures robustly predict diverse antiviral functions relevant for convalescent plasma therapy. 2020,	13
522	High affinity modified ACE2 receptors protect from SARS-CoV-2 infection in hamsters.	10
521	A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro. 2020,	4
520	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. 2020,	2
519	NeutrobodyPlex - Nanobodies to monitor a SARS-CoV-2 neutralizing immune response.	4
518	A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2.	7
517	A high-affinity RBD-targeting nanobody improves fusion partner β potency against SARS-CoV-2.	1
516	The quantitative landscape of the neutralizing antibody response to SARS-CoV-2.	2
515	A potent SARS-CoV-2 neutralizing human monoclonal antibody that reduces viral burden and disease severity in Syrian hamsters. 2020,	2
514	LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. 2020,	64
513	Potent mouse monoclonal antibodies that block SARS-CoV-2 infection.	1
512	Extremely potent human monoclonal antibodies from convalescent Covid-19 patients.	6
511	Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies.	2
510	Antibody Immunological Imprinting on COVID-19 Patients.	14
509	Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters.	5
508	Multivalency transforms SARS-CoV-2 antibodies into broad and ultrapotent neutralizers.	10
507	Structure, Dynamics, Receptor Binding, and Antibody Binding of Fully-glycosylated Full-length SARS-CoV-2 Spike Protein in a Viral Membrane.	1

506	The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.	18
505	Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations. 2020,	8
504	Identification of Cross-Reactive CD8+ T Cell Receptors with High Functional Avidity to a SARS-CoV-2 Immunodominant Epitope and Its Natural Mutant Variants.	3
503	The ACE2-binding interface of SARS-CoV-2 Spike inherently deflects immune recognition. 2020,	1
502	Rapid development of SARS-CoV-2 receptor binding domain-conjugated nanoparticle vaccine candidate.	1
501	Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3). 2021,	3
500	Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2. 2020,	10
499	Recurrent mutations in SARS-CoV-2 genomes isolated from mink point to rapid host-adaptation.	31
498	Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein.	12
497	Maturation and persistence of the anti-SARS-CoV-2 memory B cell response.	10
496	An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19. 2020,	11
495	Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. 2021,	4
494	N439K variant in spike protein may alter the infection efficiency and antigenicity of SARS-CoV-2 based on molecular dynamics simulation.	7
493	Double Lock of a Potent Human Monoclonal Antibody against SARS-CoV-2.	3
492	A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry. 2020,	6
491	A Neutralizing Antibody-Conjugated Photothermal Nanoparticle Captures and Inactivates SARS-CoV-2. 2020,	8
490	Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. 2020,	34
489	Circulating ACE2-expressing Exosomes Block SARS-CoV-2 Infection as an Innate Antiviral Mechanism.	8

488	A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to most known recently emerging RBD mutations.	8
487	The Potential for SARS-CoV-2 to Evade Both Natural and Vaccine-induced Immunity.	4
486	Targeting Scavenger Receptor Type B-1 (SR-B1) and Cholesterol Inhibits Entry of SARS-CoV-2 Pseudovirus in Cell Culture.	1
485	Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma. 2020,	29
484	mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection.	21
483	Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection. 2020,	29
482	Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors. 2020, 5,	40
481	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. 2020, 16, e1009089	33
480	Structures of the SARS-CoV-2 nucleocapsid and their perspectives for drug design. 2020, 39, e105938	74
479	SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. 2020,	12
478	Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. 2020,	7
477	From Cold to Killer: How SARS-CoV-2 Evolved without Hemagglutinin Esterase to Agglutinate, Then Clot Blood Cells in Pulmonary and Systemic Microvasculature.	2
476	Paired Heavy and Light Chain Signatures Contribute to Potent SARS-CoV-2 Neutralization in Public Antibody Responses.	1
475	Neuronal and Cerebrovascular Complications in Coronavirus Disease 2019. 2020, 11, 570031	4
474	Confronting the threat of SARS-CoV-2: Realities, challenges and therapeutic strategies (Review). 2021, 21, 155	2
473	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. 2020, 9,	784
472	antibody engineering for SARS-CoV-2 detection. 2021, 19, 5525-5534	1
471	Germinal Center-Induced Immunity Is Correlated With Protection Against SARS-CoV-2 Reinfection But Not Lung Damage. 2021, 224, 1861-1872	1

470	Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants. 2021 , 13, 164	10
469	How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika. 2021 , 13,	1
468	Long Term Immune Response Produced by the SputnikV Vaccine. 2021 , 22,	2
467	An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants. 2021 , 13,	3
466	Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection and vaccination. 2021 , 499, 113165	2
465	Kinetics of Neutralizing Antibody Response Underscores Clinical COVID-19 Progression. 2021 , 2021, 9822706	2
464	Rational preparation and application of a mRNA delivery system with cytidinyl/cationic lipid. 2021 , 340, 114-124	1
463	SARS-CoV-2 multi-variant graphene biosensor based on engineered dimeric ACE2 receptor.	1
462	Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies. 2021 , 11, 20274	8
461	The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization. 2021 , 49, 647	3
460	A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration. 2021 , 37, 109869	13
459	Structure-guided antibody cocktail for prevention and treatment of COVID-19. 2021 , 17, e1009704	6
458	An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models. 2021 , 13, eabi7826	7
457	SARS-CoV-2 seroassay performance and optimization in a population with high background reactivity in Mali. 2021 ,	7
456	Structure-selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern.	
455	Distinct BCR repertoires elicited by SARS-CoV-2 RBD and S vaccinations in mice. 2021 , 7, 91	4
454	Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments. 2021 ,	1
453	Secondary Structure and Conformational Stability of the Antigen Residues Making Contact with Antibodies. 2021 , 125, 11374-11385	1

452	Uncovering a conserved vulnerability site in SARS-CoV-2 by a human antibody. 2021 , 13, e14544	1
451	Generation and persistence of S1IgG and neutralizing antibodies in post-COVID-19 patients. 2021 , 50, 447	2
450	Key substitutions in the spike protein of SARS-CoV-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effects. 2021 , JVI0111021	7
449	Discovery and characterization of high-affinity, potent SARS-CoV-2 neutralizing antibodies via single B cell screening. 2021 , 11, 20738	6
448	Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice. 2021 , 6, 369	3
447	Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. 2021 , 9, e0135221	2
446	Early Administration of Bamlanivimab in Combination with Etesevimab Increases the Benefits of COVID-19 Treatment: Real-World Experience from the Liguria Region. 2021 , 10,	1
445	Current treatment strategies for COVID-19 (Review). 2021 , 24,	2
444	COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. 2021 , 12, 6097	15
443	Unravelling the molecular interactions between the SARS-CoV-2 RBD spike protein and various specific monoclonal antibodies. 2021 ,	2
442	SARS-CoV-2 hijacks neutralizing dimeric IgA for enhanced nasal infection and injury.	1
441	Conformational variability of loops in the SARS-CoV-2 spike protein. 2021 ,	1
440	Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization. 2021 , 4, 1196	16
439	One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization. 2021 , 10, 2016-2029	4
438	Mechanisms of Lung Injury Induced by SARS-CoV-2 Infection. 2021 ,	2
437	Monoclonal antibodies protect aged rhesus macaques from SARS-CoV-2-induced immune activation and neuroinflammation. 2021 , 37, 109942	3
436	Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern. 2021 , 7, 96	5
435	Effective chimeric antigen receptor T cells against SARS-CoV-2. 2021 , 24, 103295	5

434	Inhaled ACE2-engineered microfluidic microsphere for intratracheal neutralization of COVID-19 and calming of the cytokine storm. 2021 ,	11
433	Arcuate Nucleus Overexpression of NHLH2 Reduces Body Mass and Attenuates Obesity-Associated Anxiety/Depression-like Behavior. 2021 , 41, 10004-10022	2
432	Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants. 2021 , 7, eabj3107	7
431	Computational Design of Potent D-Peptide Inhibitors of SARS-CoV-2. 2021 , 64, 14955-14967	5
430	Epitope Analysis of Anti-SARS-CoV-2 Neutralizing Antibodies. 2021 , 41, 1065	0
429	Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses. 2021 , 218,	4
428	Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD. 2021 , 37, 109881	6
427	COVID-19 Infection and Children: A Comprehensive Review. 2020 , 11, 157	0
426	Stereotypic Neutralizing VH Clonotypes Against SARS-CoV-2 RBD in COVID-19 Patients and the Healthy Population.	4
425	Going back in time for an antibody to fight COVID-19. <i>Nature</i> , 2020 , 583, 203-204	50.4 1
424	Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike. 2020 ,	1
423	A human monoclonal antibody targeting a conserved pocket in the SARS-CoV-2 receptor-binding domain core.	1
422	Phospholipids dock SARS-CoV-2 spike protein via hydrophobic interactions: a minimal in-silico study of lecithin nasal spray therapy. 2021 , 44, 132	1
421	A Collection of Designed Peptides to Target SARS-CoV-2 Spike RBD-ACE2 Interaction. 2021 , 22,	3
420	A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load. 2021 ,	10
419	MHC-II constrains the natural neutralizing antibody response to the SARS-CoV-2 spike RBM in humans. 2020 ,	
418	Narrative review of the novel coronavirus SARS-CoV-2: update on genomic characteristics, transmissions and animal model. 2020 , 12, 7454-7466	0
417	Sterilizing immunity against SARS-CoV-2 in hamsters conferred by a novel recombinant subunit vaccine.	1

416	A SARS-CoV-2 spike binding DNA aptamer that inhibits pseudovirus infection in vitro by an RBD independent mechanism.	2
415	Dynamics of B-Cell Repertoires and Emergence of Cross-Reactive Responses in COVID-19 Patients with Different Disease Severity.	1
414	Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants by Modular, Tetravalent, Bi-paratopic Antibodies.	
413	Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses. 2021 , 7, 1863-1873	2
412	Self and Nonsel Self Short Constituent Sequences of Amino Acids in the SARS-CoV-2 Proteome for Vaccine Development. 2021 , 1, 555-574	3
411	In Vivo Electroporation of Plasmid DNA: A Promising Strategy for Rapid, Inexpensive, and Flexible Delivery of Anti-Viral Monoclonal Antibodies. 2021 , 13,	0
410	Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants. 2021 , 12, 6304	15
409	A high-throughput, automated, cell-free expression and screening platform for antibody discovery.	0
408	Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies. 2021 , 196, 105206	0
407	Fc-Independent Protection from SARS-CoV-2 Infection by Recombinant Human Monoclonal Antibodies. 2021 , 10,	2
406	Corticosteroid treatment in COVID-19 modulates host inflammatory responses and transcriptional signatures of immune dysregulation. 2021 , 110, 1225-1239	1
405	A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. 2021 , 6, 378	5
404	Discovery and Development of Human SARS-CoV-2 Neutralizing Antibodies using an Unbiased Phage Display Library Approach.	3
403	Editorial: The battle for survival between severe acute respiratory syndrome coronavirus 2 and human beings. 2020 , 15, 325-327	
402	Performance characteristics of the VIDAS [®] SARS-COV-2 IgM and IgG serological assays.	1
401	Rapid evaluation of neutralizing antibodies in COVID-19 patients.	
400	Systematic profiling of SARS-CoV-2 specific IgG epitopes at single amino acid resolution.	0
399	Surface plasmon resonance sensing in cell biology and drug discovery. 2021 , 95, 1-53	1

398	A Multifunctional Neutralizing Antibody-Conjugated Nanoparticle Inhibits and Inactivates SARS-CoV-2. 2021 , e2103240	3
397	A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display.. 2021 , 9,	1
396	The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies. 2021 , 12, 704205	13
395	Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease.	1
394	SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape. 2021 , 22,	2
393	[IgA dominates the early neutralizing antibody response to SARS-CoV-2 virus]. 2021 , 37, 968-970	1
392	Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance.. 2021 , 62, 64-73	7
391	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. 2021 , 101533	11
390	Antibody cocktail effective against variants of SARS-CoV-2. 2021 , 28, 80	6
389	Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving Tumor Necrosis Factor- α inhibitors. 2021 ,	8
388	A Strategy to Detect Emerging Non-Delta SARS-CoV-2 Variants with a Monoclonal Antibody Specific for the N501 Spike Residue. 2021 , 11,	0
387	Immunoinformatics mapping of potential epitopes in SARS-CoV-2 structural proteins. 2021 , 16, e0258645	1
386	Finger stick blood test to assess post vaccination SARS-CoV-2 neutralizing antibody response against variants.	
385	A second functional furin site in the SARS-CoV-2 spike protein. 2021 , 1-35	3
384	The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines. 2021 ,	3
383	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung.. 2021 ,	24
382	Development and characterization of a quantitative ELISA to detect anti-SARS-CoV-2 spike antibodies. 2021 , 7, e08444	0
381	Is SARS-CoV-2 viral clearance in nasopharyngeal swabs an appropriate surrogate marker for clinical efficacy of neutralising antibody-based therapeutics?. 2021 , e2314	5

380	EASINESS: Assisted Speedy affINity-maturation Evolution SyStem.. 2021 , 12, 747267		
379	Nascent perspectives on COVID-19 treatments. 2021 , 43, 329-335		
378	Corona Viruses: Emergence, Evolution, and Recurrence. 2021 , 1-40		
377	Neutralizing antibody: a savior in the Covid-19 disease.. 2022 , 1		3
376	Two-step fitness selection for intra-host variations in SARS-CoV-2.. 2021 , 110205		9
375	Dual-detection fluorescent immunochromatographic assay for quantitative detection of SARS-CoV-2 spike RBD-ACE2 blocking neutralizing antibody.. 2021 , 199, 113883		2
374	Functional nucleic acids as modular components against SARS-CoV-2: From diagnosis to therapeutics.. 2021 , 201, 113944		0
373	Potential SARS-CoV-2 Spike Protein-ACE2 Interface Inhibitors: Repurposing FDA-approved Drugs. 2022 , 000, 000-000		1
372	Predictive Profiling of SARS-CoV-2 Variants by Deep Mutational Learning.		
371	Testing Antigens, Antibodies, and Immune Cells in COVID-19 as a Public Health Topic-Experience and Outlines.. 2021 , 18,		1
370	Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.		30
369	Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.. <i>Nature</i> , 2021 ,	50.4	230
368	SARS-CoV-2-host cell surface interactions and potential antiviral therapies.. 2022 , 12, 20200081		0
367	Clinical Application of Antibody Immunity Against SARS-CoV-2: Comprehensive Review on Immunoassay and Immunotherapy.. 2022 , 1		0
366	A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants.. 2022 , 7, 23		0
365	Comparison of Wild Type DNA Sequence of Spike Protein from SARS-CoV-2 with Optimized Sequence on The Induction of Protective Responses Against SARS-Cov-2 Challenge in Mouse Model.. 2022 , 1-11		1
364	Human Organoids as a Promising Platform for Fighting COVID-19.. 2022 , 18, 901-910		1
363	Homologous or Heterologous Booster of Inactivated Vaccine Reduces SARS-CoV-2 Omicron Variant Escape from Neutralizing Antibodies.. 2022 , 1-18		15

362	mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant.. 2022,	85
361	Impact of various vaccine boosters on neutralization against Omicron following prime vaccinations with inactivated or adenovirus-vectored vaccine.	0
360	Comprehensive Evaluation of ACE2-Fc Combination with Neutralization Antibody on Broad Protection against SARS-CoV-2 and Its Variants.	1
359	Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape.	0
358	Covalent coupling of Spike's receptor binding domain to a multimeric carrier produces a high immune response against SARS-CoV-2.. 2022, 12, 692	1
357	Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection.. 2022, 3, 100528	1
356	Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. 2022, 375,	15
355	Comparative Immunogenicity of the Recombinant Receptor-Binding Domain of Protein S SARS-CoV-2 Obtained in Prokaryotic and Mammalian Expression Systems.. 2022, 10,	5
354	Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants.. 2022, 1-15	1
353	Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance.. 2022,	116
352	A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies.. 2022, 13, 462	3
351	An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer.	0
350	Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection.. 2022, 29, 1	17
349	Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2.. 2022, 13, 405	13
348	ACE2 can act as the secondary receptor in the Fc γ -dependent ADE of SARS-CoV-2 infection.. 2021, 103720	0
347	HACE2-Exosome-Based Nano-Bait for Concurrent SARS-CoV-2 Trapping and Antioxidant Therapy.. 2022,	2
346	Pandemic Strategies with Computational and Structural Biology against COVID-19: A Retrospective.. 2021,	2
345	Evaluation of Drug Repositioning by Molecular Docking of Pharmaceutical Resources to Identification of Potential SARS-CoV-2 Viral Inhibitors.	

344	Discovery of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against Omicron and Omicron + R346K Variants.	2
343	Computational Analysis of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike and Their Effects on Antibody Binding.. 2022 , 14,	2
342	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.. 2022 ,	102
341	Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection.. 2022 , 110318	2
340	Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019.. 2022 , 9, ofac053	7
339	CoVax501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity.. 2022 , 8, 9	1
338	Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score-matched retrospective cohort study.. 2022 , 106, 108570	3
337	Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance.. 2022 , 132,	0
336	Infection or a third dose of mRNA vaccine elicit neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients.. 2022 , 14, eabl6141	5
335	Development and multi-center clinical trials of an up-converting phosphor technology-based point-of-care (UPT-POCT) assay for rapid COVID-19 diagnosis and prediction of protective effects.. 2022 , 22, 42	0
334	A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques.. 2022 ,	1
333	Neutralizing monoclonal antibodies against highly pathogenic coronaviruses.. 2021 , 53, 101199	0
332	The Influence of New SARS-CoV-2 Variant Omicron (B.1.1.529) on Vaccine Efficacy, its Correlation to Delta Variants: A Computational Approach.	
331	Aerosolized Nanobodies Prevent Infections of SARS-CoV-2 in PrEP and PEP Settings in Mice and are Effective to Variants.	
330	Anti-SARS-CoV-2 Omicron Antibodies Isolated from a SARS-CoV-2 Delta Semi-Immune Phage Display Library.. 2022 , 11,	1
329	A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection.. 2022 , 14, eabi9215	15
328	An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity.. 2022 , 185, 614-629.e21	7
327	The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.. 2021 ,	156

326	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.. 2022 , 399, 665-676		43
325	Cryo-EM structure of the SARS-CoV-2 Omicron spike.. 2022 , 110428		12
324	Comprehensive Epitope Mapping of Broad Sarbecovirus Neutralizing Antibodies.		1
323	Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants.. 2022 , 7, 42		5
322	Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages.		13
321	Increased resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies.		2
320	A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants.. 2021 , 12, 766821		5
319	SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.. 2021 , 37, 110143		16
318	Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding.. 2021 , 37, 110156		11
317	Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. <i>Nature</i> ,	50.4	25
316	Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. <i>Nature</i> ,	50.4	34
315	Conformational dynamics of the Beta and Kappa SARS-CoV-2 spike proteins and their complexes with ACE2 receptor revealed by cryo-EM.. 2021 , 12, 7345		13
314	Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.. <i>Nature</i> , 2021 ,	50.4	249
313	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.. <i>Nature</i> , 2021 ,	50.4	204
312	Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2.. <i>Nature</i> , 2021 ,	50.4	227
311	Deep dissection of the antiviral immune profile of patients with COVID-19.. 2021 , 4, 1389		3
310	A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry. 2021 , 118,		4
309	The significant immune escape of pseudotyped SARS-CoV-2 Variant Omicron. 2021 , 1-11		102

308	An antibody-escape calculator for mutations to the SARS-CoV-2 receptor-binding domain.. 2021,	10
307	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.. 2021,	16
306	The Omicron variant is highly resistant against antibody-mediated neutralization [Implications for control of the COVID-19 pandemic.	13
305	Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization.	37
304	Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2.	24
303	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies.	10
302	Structural basis for antibody resistance to SARS-CoV-2 omicron variant.	3
301	Homologous or Heterologous Booster of Inactivated Vaccine Reduces SARS-CoV-2 Omicron Variant Escape from Neutralizing Antibodies.	1
300	Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529.	6
299	Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron.. 2021,	14
298	Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody.	2
297	Epitope profiling using computational structural modelling demonstrated on coronavirus-binding antibodies.. 2021, 17, e1009675	6
296	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.. 2021,	22
295	Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. 2021,	
294	Production of a Highly Immunogenic Antigen from SARS-CoV-2 by Covalent Coupling of the Receptor Binding Domain of Spike Protein to a Multimeric Carrier.	0
293	Insights from computational analysis: how does the SARS-CoV-2 Delta (B.1.617.2) variant hijack ACE2 more effectively?. 2022,	0
292	Origin of the tight binding mode to ACE2 triggered by multi-point mutations in the omicron variant: a dynamic insight.. 2022,	1
291	Prior SARS-CoV2 infection in vaccinated solid organ transplant recipients induces potent neutralization responses against variants, including Omicron.	0

290	On Correlation between Structural Properties and Viral Escape Measurements from Deep Mutational Scanning.	
289	Efficient Neutralization of SARS-CoV-2 Omicron and Other VOCs by a Broad Spectrum Antibody 8G3.	0
288	Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?. 2022 , 14, 2031483	2
287	Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant.. 2022 ,	10
286	Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies.. 2022 , 13, 835136	1
285	Analysis of B cell receptor repertoires reveals key signatures of systemic B cell response after SARS-CoV-2 infection. 2021 , JVI0160021	2
284	An engineered bispecific human monoclonal antibody against SARS-CoV-2.. 2022 ,	3
283	Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies.. 2022 , 13, 871	13
282	Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant.. 2022 , 23,	0
281	Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants.. 2022 , 18, e1010260	12
280	Evolutionary dynamics of the severe acute respiratory syndrome coronavirus 2 genomes. 2022 , 2, 3-22	0
279	Modeling how antibody responses may determine the efficacy of COVID-19 vaccines. 2022 , 2, 123-131	2
278	Nonsel self Mutations in the Spike Protein Suggest an Increase in the Antigenicity and a Decrease in the Virulence of the Omicron Variant of SARS-CoV-2. 2022 , 2, 407-418	3
277	Structure/Function Analysis of Truncated Amino-Terminal ACE2 Peptide Analogs That Bind to SARS-CoV-2 Spike Glycoprotein.. 2022 , 27,	0
276	Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering.. 2022 , 23,	0
275	Effect of monoclonal antibody therapy on the endogenous SARS-CoV-2 antibody response.. 2022 , 108959	4
274	Antibody evasion properties of SARS-CoV-2 Omicron sublineages.. <i>Nature</i> , 2022 ,	50.4 88
273	SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests.. 2022 , 12, 3351	

272	Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization.. 2022 , 119, e2122954119	1
271	Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody.. 2022 ,	6
270	An antibody-escape estimator for mutations to the SARS-CoV-2 receptor-binding domain.. 2022 , 8, veac021	3
269	Introduction of a Capillary Gel Electrophoresis-Based Workflow for Biotherapeutics Characterization: Size, Charge, and Glycosylation Variant Analysis of Bamlanivimab, an Anti-SARS-CoV-2 Product.. 2022 , 10, 839374	
268	Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires Fc γ RIIB and virus-antibody complex with bivalent interaction.. 2022 , 5, 262	1
267	The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes.. 2022 ,	6
266	Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions.. 2022 , 25, 103939	2
265	An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2.. 2022 ,	2
264	Seroneutralization of Omicron BA.1 and BA.2 in patients receiving anti-SARS-CoV-2 monoclonal antibodies.	0
263	Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking.. 2022 ,	6
262	Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529.. 2022 , 376, eabn8897	18
261	No substantial pre-existing B cell immunity against SARS-CoV-2 in healthy adults.. 2022 , 103951	1
260	Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: A Phase 2/3, Multicenter, Randomized, Open-label, Controlled Trial.. 2022 , AAC0204521	1
259	Global trends in COVID-19. 2022 ,	1
258	Rapid and Quantitative Evaluation of SARS-CoV-2 Neutralizing Antibodies and Nanobodies.. 2022 ,	1
257	Recent advances of functional nucleic acid-based sensors for point-of-care detection of SARS-CoV-2.. 2022 , 189, 128	0
256	Topologically engineered antibodies and Fc-fusion proteins: a new class of multifunctional therapeutic candidates for SARS-CoV-2, cancer, and other disease.	
255	Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.. 2022 ,	22

254	Unbinding of hACE2 and inhibitors from the receptor binding domain of SARS-CoV-2 spike protein.. 2022 , 1-20	
253	Monobodies with potent neutralizing activity against SARS-CoV-2 Delta and other variants of concern.. 2022 , 5,	0
252	Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal models.. 2022 ,	2
251	Potent Human Broadly SARS-CoV-2 Neutralizing IgA and IgG Antibodies Effective Against Omicron BA.1 and BA.2.	0
250	Antiviral Cell Products against COVID-19: Learning Lessons from Previous Research in Anti-Infective Cell-Based Agents.. 2022 , 10,	
249	Molecular docking study involving bioactive natural compounds against SARS-CoV-2 proteins.	0
248	Two Different Therapeutic Approaches for SARS-CoV-2 in hiPSCs-Derived Lung Organoids.. 2022 , 11,	2
247	Epitope mapping of neutralising anti-SARS-CoV-2 monoclonal antibodies: Implications for immunotherapy and vaccine design.. 2022 , e2347	1
246	Future Prospects for Biomolecular Trapping with Nanostructured Metals.	1
245	MutCov: A pipeline for evaluating the effect of mutations in spike protein on infectivity and antigenicity of SARS-CoV-2.. 2022 , 145, 105509	1
244	Antibody Resistance of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 and BA.3 Sub-lineages.	2
243	Systematic profiling of antigen bias in humoral response against SARS-CoV-2.. 2022 , 198711	
242	Analysis of SARS-CoV-2 Variants B.1.617: host tropism, proteolytic activation, cell-cell fusion, and neutralization sensitivity.. 2022 , 1-32	0
241	Landscape-Based Protein Stability Analysis and Network Modeling of Multiple Conformational States of the SARS-CoV-2 Spike D614G Mutant: Conformational Plasticity and Frustration-Induced Allosteric as Energetic Drivers of Highly Transmissible Spike Variants.. 2022 ,	0
240	David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors.. 2022 , 14, 2057832	2
239	Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.. 2022 , 201, 105297	1
238	The role of antigen-presenting cells in the pathogenesis of COVID-19.. 2022 , 233, 153848	3
237	mRNA vaccines for COVID-19 and diverse diseases.. 2022 , 345, 314-333	9

236	Lysine Hydroxybutyrylation Improves Stability of COVID-19 Antibody. 2021,	0
235	Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant.	
234	Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy. 2022, 2,	1
233	Conformational Flexibility and Local Frustration in the Functional States of the SARS-CoV-2 Spike B.1.1.7 and B.1.351 Variants : Mutation-Induced Allosteric Modulation Mechanism of Functional Dynamics and Protein Stability.	0
232	Predictive profiling of SARS-CoV-2 variants by deep mutational learning.	0
231	The Landscape-Based Protein Stability Analysis and Network Modeling of Multiple Conformational States of the SARS-CoV-2 Spike D614 Mutant: Conformational Plasticity and Frustration-Driven Allostery as Energetic Drivers of Highly Transmissible Spike Variant.	
230	Intranasal inhibitor blocks Omicron and other variants of SARS-CoV-2.	
229	The effect of anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, on endogenous immune response to COVID-19 vaccination.	0
228	Modeling and predicting the overlap of B- and T-cell receptor repertoires in healthy and SARS-CoV-2 infected individuals.	0
227	Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives.. 2021, 14,	3
226	Quality comparability assessment of a SARS-CoV-2-neutralizing antibody across transient, mini-pool-derived and single-clone CHO cells.. 2022, 14, 2005507	1
225	COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review.. 2022, 12, 15	3
224	The influence of new SARS-CoV-2 variant Omicron (B.1.1.529) on vaccine efficacy, its correlation to Delta Variants: a computational approach.	
223	Inhibition of Viral Membrane Fusion by Peptides and Approaches to Peptide Design.. 2021, 10,	3
222	Bamlanivimab plus etesevimab treatment have a better outcome against COVID-19: A meta-analysis.. 2021,	2
221	Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.. 2021, 12, 790469	6
220	Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection.. 2022, e0155321	3
219	A SARS-CoV-2 antibody retains potent neutralization against Omicron by targeting conserved RBM residues.. 2022,	0

218	A high potent synthetic nanobody with broad-spectrum activity neutralizes SARS-Cov-2 virus and Omicron variant through a unique binding mode.	
217	Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain.. 2022 , 1-11	1
216	Dermal Delivery of a SARS-CoV-2 Subunit Vaccine Induces Immunogenicity against Variants of Concern.. 2022 , 10,	0
215	Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity had no antiviral effects but moderately reduced lung inflammation.. 2022 , 18, e1009925	0
214	SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination.. 2022 , 110754	0
213	Isolation, characterization, and structure-based engineering of a neutralizing nanobody against SARS-CoV-2.. 2022 ,	0
212	Identification of B-Cell Epitopes for Eliciting Neutralizing Antibodies against the SARS-CoV-2 Spike Protein through Bioinformatics and Monoclonal Antibody Targeting.. 2022 , 23,	3
211	Nanomaterials and metal-organic frameworks for biosensing applications of mutations of the emerging viruses.. 2022 , 114680	0
210	Generation and Characterization of Humanized Synergistic Neutralizing Antibodies against SARS-CoV-2.. 2022 ,	0
209	Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies.. 2022 , 78, 103944	7
208	Omicron BA.2 (B.1.1.529.2): High Potential for Becoming the Next Dominant Variant.. 2022 , 3840-3849	13
207	The relationship between IgG and IgM levels and severity of symptoms in COVID-19 patients confirmed by rapid antigen test.. 2021 , 14, 790-796	0
206	Clinical update on the use of mesenchymal stem cells in COVID-19.. 2021 , 13, 12195-12205	0
205	Implementation of level-2 biosafety for a macromolecular crystallography beamline at SSRF.. 2021 , 11, 529-536	
204	Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant.. 2022 ,	
203	Computational approach for binding prediction of SARS-CoV-2 with neutralizing antibodies.. 2022 ,	0
202	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.. 2022 ,	3
201	An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer.. 2022 ,	1

200	Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2.. 2022,	8
199	Potential for a Plant-Made SARS-CoV-2 Neutralizing Monoclonal Antibody as a Synergetic Cocktail Component. 2022, 10, 772	3
198	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.	9
197	COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants.. 2022, 12, 7168	1
196	Pharmacological and non-pharmacological strategies in coronavirus disease 2019: A literature review.. 2022, 77, 103709	
195	SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies.. 2022,	2
194	Monoclonal Antibodies as Potential COVID-19 Therapeutic Agents. 2022, 2, 599-620	0
193	Antibody Evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 and BA.3 Sub-lineages. 2022,	10
192	Non-glycosylated SARS-CoV-2 RBD elicited a robust neutralizing antibody response in mice.. 2022, 506, 113279	0
191	Virtual and biochemical screening to identify the inhibitors of binding between SARS-CoV-2 spike protein and human angiotensin-converting enzyme 2.. 2022, 114, 108206	0
190	Antibody-Mediated Neutralization of SARS-CoV-2. 2022,	5
189	Improving antibody affinity through mutagenesis in complementarity determining regions.. 2022, 1-13	1
188	Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants by Modular, Tetravalent, Bi-paratopic Antibodies. 2022, 110905	0
187	The assembled and annotated genome of the masked palm civet (<i>Paguma larvata</i>).. 2022, 11,	1
186	A Bacterially Expressed SARS-CoV-2 Receptor Binding Domain Fused With Cross-Reacting Material 197 A-Domain Elicits High Level of Neutralizing Antibodies in Mice.. 2022, 13, 854630	1
185	Mathematical artificial intelligence design of mutation-proof COVID-19 monoclonal antibodies.. 2022,	
184	Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice.	
183	Peptide derived nanobody inhibits entry of SARS-CoV-2 variants.	

182	Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease. 2022 , 7,	1
181	Animal models for studying coronavirus infections and developing antiviral agents and vaccines. 2022 , 203, 105345	1
180	Native, engineered and de novo designed ligands targeting the SARS-CoV-2 spike protein. 2022 , 59, 107986	0
179	The Endothelium and COVID-19: An Increasingly Clear Link Brief Title: Endotheliopathy in COVID-19. 2022 , 23, 6196	3
178	Healthy humans can be a source of antibodies countering COVID-19. 2022 , 13, 12598-12624	
177	Protective neutralizing epitopes in SARS-CoV-2.	3
176	Structural and functional analysis of an inter-Spike bivalent neutralizing antibody against SARS-CoV-2 variants. 2022 , 104431	1
175	Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron. 2022 , 17, e0268767	1
174	SARS-CoV-2 Omicron BA.2.12.1, BA.4, and BA.5 subvariants evolved to extend antibody evasion.	3
173	Performance analysis among multiple fully automated anti-SARS-CoV-2 antibody measurement reagents: A potential indicator for the correlation of protection in the antibody titer. 2022 ,	0
172	Evaluation of strategies to modify Anti-SARS-CoV-2 monoclonal antibodies for optimal functionality as therapeutics. 2022 , 17, e0267796	0
171	Atrial fibrillation with aberrant ventricular conduction after receiving Bamlanivimab/Etesevimab: a case report. 1-3	0
170	Protective human anti-poxvirus monoclonal antibodies are generated from rare memory B cells isolated by multicolor antigen tetramers.	0
169	A universal DNA aptamer as an efficient inhibitor against spike-protein/hACE2 interactions.	0
168	Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2.	7
167	Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy. 2022 , 29,	
166	SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2. 13,	0
165	The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination.	2

- 164 Depending on Epitope Profile of COVID-19 mRNA Vaccine Recipients: Are They More Efficient Against the Arising Viral Variants? An Opinion Article. 9,
- 163 Predicting the antigenic evolution of SARS-CoV-2 with deep learning. 0
- 162 Mutational insights among the structural proteins of SARS-CoV-2: frequencies and evolutionary trends in American countries.
- 161 Venetoclax Decreases the Expression of the Spike Protein through Amino Acids Q493 and S494 in SARS-CoV-2. **2022**, 11, 1924 0
- 160 Atlas of currently-available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3. **2022**, 2
- 159 BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. *Nature*, 504 85
- 158 Immune Response to SARS-CoV-2 Vaccines. **2022**, 10, 1464 2
- 157 Induction of Broadly Cross-Reactive Antibody Responses to SARS-CoV-2 Variants by S1 Nanoparticle Vaccines. 0
- 156 Antibodies to combat viral infections: development strategies and progress. 5
- 155 Potent human broadly SARS-CoV-2 neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. **2022**, 219, 3
- 154 Lessons from SARS-CoV-2 and its variants (Review). **2022**, 26, 0
- 153 The influence of new SARS-CoV-2 variant Omicron (B.1.1.529) on vaccine efficacy, its correlation to Delta variants: A computational approach. **2022**, 105619 0
- 152 Nasal Spray of Neutralizing Monoclonal Antibody 35B5 Confers Potential Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern (VOCs): A Small-scale Clinical Trial. 1
- 151 Binding and structural basis of equine ACE2 to RBDs from SARS-CoV, SARS-CoV-2 and related coronaviruses. **2022**, 13, 1
- 150 Applications of nanoengineered therapeutics and vaccines: special emphasis on COVID-19. **2022**, 21-63
- 149 Broadly Neutralizing Antibodies Against Omicron Variants of SARS-CoV-2 Derived from mRNA-Lipid Nanoparticle-Immunized Mice.
- 148 Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2. **2022**, 7, 1063-1074 4
- 147 Immune Escape Mechanisms of SARS-CoV-2 Delta and Omicron Variants against Two Monoclonal Antibodies That Received Emergency Use Authorization. **2022**, 13, 6064-6073 2

146	The humoral response and antibodies against SARS-CoV-2 infection. 2022 , 23, 1008-1020	2
145	SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. 2022 ,	3
144	Nanobodies: COVID-19 and Future Perspectives. 2,	0
143	Application of Baculovirus Expression Vector system (BEV) for COVID-19 diagnostics and therapeutics: a review. 2022 , 20,	0
142	Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models.	6
141	Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, & BA.5. <i>Nature</i> ,	50.4 50
140	Protective Human Anti-Poxvirus Monoclonal Antibodies Are Generated from Rare Memory B Cells Isolated by Multicolor Antigen Tetramers. 2022 , 10, 1084	1
139	The trisppecific DARPIn ensovibep inhibits diverse SARS-CoV-2 variants.	1
138	Neutralizing antibody evasion and receptor binding features of SARS-CoV-2 Omicron BA.2.75.	2
137	Modern antiviral biomedical cell products and their applications for COVID-19 therapy. 2022 , 21, 19-32	
136	Structure-selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern. 2022 , 18, e1010686	
135	Immune Evasion by the Highly Mutated SARS-CoV-2 Omicron Variant. Volume 15, 4013-4027	0
134	Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses. 2022 , 7,	1
133	Decoding the Effects of Spike Receptor Binding Domain Mutations on Antibody Escape Abilities of Omicron Variants.	
132	Case Report: Subacute thyroiditis after receiving inactivated SARS-CoV-2 vaccine (BBIBP-CorV). 9,	1
131	Targeting the Receptor-Binding Motif of SARS-CoV-2 with D-Peptides Mimicking the ACE2 Binding Helix: Lessons for Inhibiting Omicron and Future Variants of Concern. 2022 , 62, 3618-3626	1
130	Evasion of neutralizing antibodies by Omicron sublineage BA.2.75.	1
129	A multispecific antibody confers pan-reactive SARS-CoV-2 neutralization and prevents immune escape.	1

128	Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75.	1
127	Balance between maternal antiviral response and placental transfer of protection in gestational SARS-CoV-2 infection.	
126	Identification of antiviral peptide inhibitors for RBD binding domain of SARS-CoV-2 omicron and its sub-variants: an in-silico approach. 2022 , 12,	0
125	Evolutionary progression of collective mutations in Omicron sub-lineages towards efficient RBD-hACE2: allosteric communications between and within viral and human proteins. 2022 ,	0
124	Discovery and Intranasal Administration of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against multiple Omicron sub variants. 2022 ,	2
123	Physical-chemical regulation of membrane receptors dynamics in viral invasion and immune defense. 2022 , 167800	0
122	Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents.	0
121	TITLE: Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways. 2022 , 104914	0
120	Computational pipeline provides mechanistic understanding of Omicron variant of concern neutralizing engineered ACE2 receptor traps.	
119	mRNA vaccines and hybrid immunity use different B cell germlines to neutralize Omicron BA.4 and BA.5.	2
118	The diversity of the glycan shield of sarbecoviruses closely related to SARS-CoV-2.	
117	Epitopes mapped onto SARS-CoV-2 receptor-binding motif by five distinct human neutralising antibodies. 1-11	
116	Natural variations within the glycan shield of SARS-CoV-2 impact viral spike dynamics.	0
115	Two Years into the COVID-19 Pandemic: Lessons Learned.	4
114	Evolutionary progression of collective mutations in Omicron sub-lineages towards efficient RBD-hACE2: allosteric communications between and within viral and human proteins.	
113	Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.	
112	The SARS-CoV-2 Antibodies, Their Diagnostic Utility, and Their Potential for Vaccine Development. 2022 , 10, 1346	0
111	Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants.	1

110	An antibody that neutralizes SARS-CoV-1 and SARS-CoV-2 by binding to a conserved spike epitope outside the receptor binding motif.	1
109	Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques. 2022 , 14,	1
108	Monoclonal antibodies: a remedial approach to prevent SARS-CoV-2 infection. 2022 , 12,	1
107	Treatment of COVID-19 by monoclonal antibodies and the traditional Chinese medicine. 2022 , 15, 100159	
106	Decoding the effects of spike receptor binding domain mutations on antibody escape abilities of omicron variants. 2022 , 627, 168-175	0
105	Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses. 2022 , 4, 100054	0
104	Self-Designed Antifouling Cyclic Peptides for Electrochemical Antigen Testing of COVID-19 in Human Blood.	0
103	Antibody-mediated immunity to SARS-CoV-2 spike. 2022 , 1-69	0
102	Differential persistence of neutralizing antibody against SARS-CoV-2 in post immunized Bangladeshi population. 2022 , 12,	0
101	Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies. 2022 , 23, 9763	4
100	Deep mutational learning predicts ACE2 binding and antibody escape to combinatorial mutations in the SARS-CoV-2 receptor-binding domain. 2022 ,	3
99	Screening and Characterization of Shark-Derived VNARs against SARS-CoV-2 Spike RBD Protein. 2022 , 23, 10904	0
98	In situ analysis of nanoparticle soft corona and dynamic evolution. 2022 , 13,	3
97	In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a Semi-Immune Phage Display Library. 2022 , 11, 57	1
96	Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies. 1-30	0
95	The Development of ELISA-test System for Detection of Specific IgG to SARS-COV-2 Coronavirus by Immunoblotting (Line Blot). 2022 , 21, 103-112	0
94	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2. 13,	1
93	An antibody cocktail with broadened mutational resistance and effective protection against SARS-CoV-2.	1

92	Epitope mapping of severe acute respiratory syndrome coronavirus 2 neutralizing receptor binding domain-specific monoclonal antibodies. 9,	1
91	Production of two SARS-CoV-2 neutralizing antibodies with different potencies in <i>Nicotiana benthamiana</i> . 13,	0
90	First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy Adults.	0
89	Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. 13,	0
88	Engineering recombinantly expressed lectin-based antiviral agents. 12,	0
87	Spatial- and Valence-Matched Neutralizing DNA Nanostructure Blocks Wild-Type SARS-CoV-2 and Omicron Variant Infection. 2022 , 16, 15310-15317	1
86	Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants. 2022 , 111528	0
85	An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV -2.	1
84	Discovery and characterization of SARS-CoV-2 reactive and neutralizing antibodies from humanized CAMouseHG mice through rapid hybridoma screening and high-throughput single-cell V(D)J sequencing. 13,	1
83	A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile.	0
82	A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode. 2022 , 20,	0
81	Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75. 2022 ,	3
80	Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses.	5
79	Anti-SARS-CoV-2 immunoadhesin remains effective against Omicron and other emerging variants of concern. 2022 , 105193	1
78	A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. 2022 , 29,	5
77	Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan-coronavirus vaccines.	1
76	Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies. 2022 , 8,	0
75	Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75. 2022 ,	5

74	A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core. 2022 , 85, 104297	1
73	A neutralizing-protective supersite of human monoclonal antibodies for yellow fever virus. 2022 , 3, 100323	1
72	Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster. 2022 , 105465	0
71	Pandemic's silver lining. 2022 , 14,	0
70	Evolving understanding of antibody-dependent enhancement (ADE) of SARS-CoV-2. 13,	1
69	A Guide to COVID-19 Antiviral Therapeutics: A Summary and Perspective of the Antiviral Weapons Against SARS-CoV-2 Infection.	1
68	Efficacy and safety of three passive immunotherapies for Corona Virus Disease 2019:a system review and network meta-analysis.	0
67	Plant Molecular Pharming and Plant-Derived Compounds towards Generation of Vaccines and Therapeutics against Coronaviruses. 2022 , 10, 1805	0
66	Stability of SARS-CoV-2 spike antigens against mutations.	0
65	Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective study. 2022 , 22,	0
64	Pan-neutralizing, germline-encoded antibodies against SARS-CoV-2: Addressing the long-term problem of escape variants. 13,	0
63	Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody to antigenically distinct omicron SARS-CoV-2 subvariants.	0
62	Enhanced stability of the SARS CoV-2 spike glycoprotein trimer following modification of an alanine cavity in the protein core.	0
61	Establishment and clinical application of SARS-CoV-2 catch column.	0
60	The effect of mutations on binding interactions between the SARS-CoV-2 receptor binding domain and neutralizing antibodies B38 and CB6. 2022 , 12,	0
59	A novel plant-made monoclonal antibody enhances the synergetic potency of an antibody cocktail against the SARS-CoV-2 Omicron variant.	1
58	Nanobody derived using a peptide epitope from the spike protein receptor-binding motif inhibits entry of SARS-CoV-2 variants. 2023 , 299, 102732	0
57	A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modeling. 2022 , 37, 1	0

56	Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies.	0
55	Impact of BA.1, BA.2, and BA.4/BA.5 Omicron Mutations on Therapeutic Monoclonal Antibodies.	2
54	Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldhydrogel \square 85 Protects K18-hACE2 Mice against Lethal Virus Challenge. 2022 , 10, 2119	0
53	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. 2022 ,	0
52	Variations within the glycan shield of SARS-CoV-2 impact viral spike dynamics. 2022 , 167928	0
51	Atomic-Level Thermodynamics Analysis of the Binding Free Energy of SARS-CoV -2 Neutralizing Antibodies.	0
50	Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. 2022 , 41, 111845	3
49	Neutralizing and enhancing antibodies against SARS-CoV-2. 2022 , 42,	0
48	Cross-reaction of current available SARS-CoV-2 MAbs against the pangolin-origin coronavirus GX/P2V/2017. 2022 , 41, 111831	0
47	A visual detection strategy for SARS-CoV-2 based on dual targets-triggering DNA walker. 2022 , 133252	0
46	Mutations in SARS-CoV-2 structural proteins: a global analysis. 2022 , 19,	1
45	Susceptibility of SARS Coronavirus-2 infection in domestic and wild animals: a systematic review. 2023 , 13,	1
44	Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccinees. 2023 , 220,	1
43	Dendrimer-Peptide Conjugates for Effective Blockade of the Interactions between SARS-CoV-2 Spike Protein and Human ACE2 Receptor.	1
42	Novel Affibody Molecules Specifically Bind to SARS-CoV-2 Spike Protein and Efficiently Neutralize Delta and Omicron Variants.	0
41	Potent Immunogenicity and Broad-Spectrum Protection Potential of Microneedle Array Patch-Based COVID-19 DNA Vaccine Candidates Encoding Dimeric RBD Chimera of SARS-CoV and SARS-CoV-2 Variants.	1
40	Two pan-SARS-CoV-2 nanobodies and their multivalent derivatives effectively prevent Omicron infections in mice. 2023 , 100918	0
39	Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5. 2023 , 9,	0

38	A Review on COVID-19: Primary Receptor, Endothelial Dysfunction, Related Comorbidities, and Therapeutics.	o
37	An alpaca-derived nanobody recognizes a unique conserved epitope and retains potent activity against the SARS-CoV-2 omicron variant.	o
36	High-Affinity Antibodies Designing of SARS-CoV-2 Based on Molecular Dynamics Simulations. 2023 , 24, 481	1
35	An inactivated recombinant rabies virus chimerically expressed RBD induces humoral and cellular immunity against SARS-CoV-2 and RABV. 2022 ,	o
34	COVID-19: Inpatient Management. 2023 , 182-232	o
33	Immunogenicity Characterization of COVID-19 Vaccines: A Systematic Review and Meta-analysis. 56,	o
32	The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics.	o
31	A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy. 2023 , 19, e1011085	o
30	A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529). Volume 18, 353-367	o
29	Lung Ultrasound Is Useful for Evaluating Lung Damage in COVID-19 Patients Treated with Bamlanivimab and Etesevimab: A Single-Center Pilot Study. 2023 , 59, 203	o
28	Currently available COVID-19 management options. 2023 , 111-124	o
27	Discovery and Optimization of Neutralizing SARS-CoV-2 Antibodies Using ALTHEA Gold Plus Libraries 2023 , 24, 4609	o
26	Liposome-based high-throughput and point-of-care assays toward the quick, simple, and sensitive detection of neutralizing antibodies against SARS-CoV-2 in patient sera. 2023 , 415, 1421-1435	o
25	The role of N-glycosylation in spike antigenicity for the SARS-CoV-2 Gamma variant.	o
24	Negative Conversion of Polymerase Chain Reaction and Clinical Outcomes according to the SARS-CoV-2 Variant in Critically Ill Patients with COVID-19. 2023 , 86, 142-149	o
23	Antibody isotype epitope mapping of SARS-CoV-2 Spike RBD protein: Targets for COVID-19 symptomatology and disease control. 2023 , 53,	o
22	Validation of a SARS-CoV-2 Surrogate Virus Neutralization Test in Recovered and Vaccinated Healthcare Workers. 2023 , 15, 426	o
21	A Competitive Panning Method Reveals an Anti-SARS-CoV-2 Nanobody Specific for an RBD-ACE2 Binding Site. 2023 , 11, 371	o

- 20 A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies Against Multiple SARS-CoV-2 Variants Including the Currently Circulating Omicron BF.5, BF.7, BQ.1 and XBB. ○
- 19 A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile. **2023**, 4, 100955 ○
- 18 An inhaled bioadhesive hydrogel to shield non-human primates from SARS-CoV-2 infection. ○
- 17 Computational pipeline provides mechanistic understanding of Omicron variant of concern neutralizing engineered ACE2 receptor traps. **2023**, 31, 253-264.e6 ○
- 16 OligoBinders: Bioengineered Soluble Amyloid-like Nanoparticles to Bind and Neutralize SARS-CoV-2. **2023**, 15, 11444-11457 ○
- 15 Broadly effective ACE2 decoy proteins protect mice from lethal SARS-CoV-2 infection. ○
- 14 Modeling and predicting the overlap of B- and T-cell receptor repertoires in healthy and SARS-CoV-2 infected individuals. **2023**, 19, e1010652 ○
- 13 SARS-CoV-2 Spike-Mediated Entry and Its Regulation by Host Innate Immunity. **2023**, 15, 639 ○
- 12 Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants. **2023**, 133, ○
- 11 Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants. **2023**, 212, 105576 ○
- 10 SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors. **2023**, 95, ○
- 9 Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies. 14, ○
- 8 Abiotic Synthetic Antibody Inhibitor with Broad-Spectrum Neutralization and Antiviral Efficacy against Escaping SARS-CoV-2 Variants. **2023**, 17, 7017-7034 ○
- 7 mRNA vaccines and hybrid immunity use different B cell germlines against Omicron BA.4 and BA.5. **2023**, 14, ○
- 6 A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB. **2023**, 11, 778 ○
- 5 Mechanism of a rabbit monoclonal antibody broadly neutralizing SARS-CoV-2 variants. **2023**, 6, ○
- 4 Therapeutics for COVID-19. **2024**, 282-307 ○
- 3 Antibodies that neutralize all current SARS-CoV-2 variants of concern by conformational locking. ○

- 2 Potent Immunogenicity and Broad-Spectrum Protection Potential of Microneedle Array Patch-Based COVID-19 DNA Vaccine Candidates Encoding Dimeric RBD Chimera of SARS-CoV and SARS-CoV-2 Variants. ○
- 1 Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice. **2023**, e15587 ○